Interestingly, the tumour microenvironment of MBM was also observed to be highly enriched with T-cell co-stimulatory signals such as CD40 and CD137, suggesting that strategies that include agonistic co-stimulation of these receptors might increase ICB response and overall survival in patients with MBM. The gene discussed is TNFRSF9; the disease is neoplasm.